Visiongain’ has launched a new Pharmaceutical Report Vaccine Sales Market Forecast 2018-2028: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra

A new report by visiongain forecasts that overall sales of human vaccines will reach $61.1 billion worldwide in 2022. That revenue growth will continue steadily through to 2028, especially with advances in vaccine technology. That revenue prediction and others appear in Vaccine Sales Market Forecast 2018-2028: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra

“Vaccinations save billions of dollars each year by avoiding vaccine-preventable infections and reducing the disease and economic burden globally. As the world moves towards an ageing population, the elderly become more susceptible to contracting infections owing to their pre-existing conditions and weaker immune system, thereby boosting the demand for vaccines. Furthermore, high birth rates with poor sanitary conditions, but increasingly improved health care systems and vaccination routines in the emerging markets will greatly fuel demand for vaccines.

Although the vaccine industry makes up a small segment for pharmaceutical companies, it represents a dynamic and robust growth market. With the increased awareness of the benefits of vaccinations across the world, the demand for immunisation programmes increases. Furthermore, developments in vaccine technology, delivery, efficacy and novel disease targeting will drive the long-term growth of the human vaccines industry.” – Pharmaceutical Industry Analyst

Visiongain’s new investigation gives individual revenue predictions to 2028 for four vaccine submarkets at world level:

• Paediatric vaccines
• Adult vaccines
• Elderly vaccines
• Travel vaccines.

That analysis also shows 10 revenue forecasts to 2028 for leading vaccines, including these:

• Prevnar
• Gardasil
• Fluzone
• Pentacel
• ProQuad/M-M-R- II/Varivax.

The study also shows prospects for vaccine sales in developed and developing regions, with individual revenue forecasts to 2028 for 11 countries:

• United States (US)
• Japan
• Germany, France, United Kingdom, Italy and Spain
• Brazil, Russia, India and China.

In particular the analysis explores these six market leaders:

• GlaxoSmithKline
• Merck & Co.
• Sanofi
• Pfizer
• Johnson & Johnson
• AstraZeneca.

Visiongain’s updated report also analyses vaccines in research and development:

• Prophylactic vaccines
• Products for children
• Agents for protecting adults
• Treatments for older people
• Travel vaccination
• Therapeutic vaccines.

Vaccine Sales Market Forecast 2018-2028: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.